153 related articles for article (PubMed ID: 32471565)
21. KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
Dempke WCM; Reck M
Lung Cancer; 2021 Sep; 159():10-17. PubMed ID: 34303275
[TBL] [Abstract][Full Text] [Related]
22. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
Arolt C; Dugan M; Wild R; Richartz V; Holz B; Scheel AH; Brägelmann J; Wagener-Ryczek S; Merkelbach-Bruse S; Wolf J; Buettner R; Catanzariti L; Scheffler M; Hillmer AM
J Thorac Oncol; 2023 Nov; 18(11):1550-1567. PubMed ID: 37473958
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and Prognostic Significance of Keap1 mRNA Expression for Lung Cancer Based on Microarray and Clinical Information from Oncomine Database.
Liu GY; Zhang W; Chen XC; Wu WJ; Wan SQ
Curr Med Sci; 2021 Jun; 41(3):597-609. PubMed ID: 34169426
[TBL] [Abstract][Full Text] [Related]
24. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
Paik PK; Fan PD; Qeriqi B; Namakydoust A; Daly B; Ahn L; Kim R; Plodkowski A; Ni A; Chang J; Fanaroff R; Ladanyi M; de Stanchina E; Rudin CM
J Thorac Oncol; 2023 Apr; 18(4):516-526. PubMed ID: 36240971
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
Shaverdian N; Offin M; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Hellmann MD; Rimner A; Paik PK; Chaft JE; Gomez DR
J Thorac Oncol; 2021 Aug; 16(8):1392-1402. PubMed ID: 33992811
[TBL] [Abstract][Full Text] [Related]
26. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
[TBL] [Abstract][Full Text] [Related]
27. Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments.
Nadal E; Palmero R; Muñoz-Pinedo C
J Thorac Oncol; 2019 Nov; 14(11):1881-1883. PubMed ID: 31668314
[No Abstract] [Full Text] [Related]
28. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma.
Best SA; Ding S; Kersbergen A; Dong X; Song JY; Xie Y; Reljic B; Li K; Vince JE; Rathi V; Wright GM; Ritchie ME; Sutherland KD
Nat Commun; 2019 Sep; 10(1):4190. PubMed ID: 31519898
[TBL] [Abstract][Full Text] [Related]
29.
Binkley MS; Jeon YJ; Nesselbush M; Moding EJ; Nabet BY; Almanza D; Kunder C; Stehr H; Yoo CH; Rhee S; Xiang M; Chabon JJ; Hamilton E; Kurtz DM; Gojenola L; Owen SG; Ko RB; Shin JH; Maxim PG; Lui NS; Backhus LM; Berry MF; Shrager JB; Ramchandran KJ; Padda SK; Das M; Neal JW; Wakelee HA; Alizadeh AA; Loo BW; Diehn M
Cancer Discov; 2020 Dec; 10(12):1826-1841. PubMed ID: 33071215
[TBL] [Abstract][Full Text] [Related]
30. EMSY stabilization in KEAP1-mutant lung cancer disrupts genome stability and type I interferon signaling.
Sheban D; Merbl Y
Cell Death Differ; 2023 May; 30(5):1397-1399. PubMed ID: 36959246
[No Abstract] [Full Text] [Related]
31. KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously".
Scalera S; Mazzotta M; Cappuzzo F; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2022 Mar; 17(3):e40-e41. PubMed ID: 35216740
[No Abstract] [Full Text] [Related]
32. Probing Mutant KRAS, STK11, KEAP1 in NSCLC.
Cancer Discov; 2022 Oct; 12(10):2226. PubMed ID: 35997519
[TBL] [Abstract][Full Text] [Related]
33. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
Zhang B; Ma Z; Tan B; Lin N
Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
[TBL] [Abstract][Full Text] [Related]
34. XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy.
Li X; Zou B; Wang S; Wang L; Yu J
J Transl Med; 2021 Oct; 19(1):421. PubMed ID: 34627293
[No Abstract] [Full Text] [Related]
35. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
36. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors.
Sparaneo A; Fabrizio FP; la Torre A; Graziano P; Di Maio M; Fontana A; Bisceglia M; Rossi A; Pizzolitto S; De Maglio G; Tancredi A; Grimaldi F; Balsamo T; Centra F; Manzorra MC; Trombetta D; Pantalone A; Bonfitto A; Maiello E; Fazio VM; Muscarella LA
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126053
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic mutations in KEAP1 disturbing inhibitory Nrf2-Keap1 interaction: Activation of antioxidative pathway in papillary thyroid carcinoma.
Danilovic DLS; de Mello ES; Frazzato EST; Wakamatsu A; de Lima Jorge AA; Hoff AO; Marui S
Head Neck; 2018 Jun; 40(6):1271-1278. PubMed ID: 29469959
[TBL] [Abstract][Full Text] [Related]
38. The negative relationship between patients with NSCLC harbored STK11/KEAP1 copy number variation and immune microenvironment infiltration.
Zhang C
J Transl Med; 2021 Jun; 19(1):259. PubMed ID: 34127019
[No Abstract] [Full Text] [Related]
39. Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1.
Romero R; Sánchez-Rivera FJ; Westcott PMK; Mercer KL; Bhutkar A; Muir A; González Robles TJ; Lamboy Rodríguez S; Liao LZ; Ng SR; Li L; Colón CI; Naranjo S; Beytagh MC; Lewis CA; Hsu PP; Bronson RT; Vander Heiden MG; Jacks T
Nat Cancer; 2020 Jun; 1(6):589-602. PubMed ID: 34414377
[TBL] [Abstract][Full Text] [Related]
40. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
Scalera S; Ricciuti B; Mazzotta M; Calonaci N; Alessi JV; Cipriani L; Bon G; Messina B; Lamberti G; Di Federico A; Pecci F; Milite S; Krasniqi E; Barba M; Vici P; Vecchione A; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Buglioni S; Pescarmona E; Sharma B; Felt KD; Lindsay J; Rodig SJ; De Maria R; Caravagna G; Cappuzzo F; Ciliberto G; Awad MM; Maugeri-Saccà M
Ann Oncol; 2023 Mar; 34(3):275-288. PubMed ID: 36526124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
